533 related articles for article (PubMed ID: 23831952)
1. Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice.
Quik M; Campos C; Grady SR
Biochem Pharmacol; 2013 Oct; 86(8):1153-62. PubMed ID: 23831952
[TBL] [Abstract][Full Text] [Related]
2. Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice.
Quik M; Park KM; Hrachova M; Mallela A; Huang LZ; McIntosh JM; Grady SR
Neuropharmacology; 2012 Sep; 63(3):450-9. PubMed ID: 22579614
[TBL] [Abstract][Full Text] [Related]
3. Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors.
Huang LZ; Grady SR; Quik M
J Pharmacol Exp Ther; 2011 Sep; 338(3):932-41. PubMed ID: 21665941
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
Bordia T; McGregor M; McIntosh JM; Drenan RM; Quik M
Neuroscience; 2015 Jun; 295():187-97. PubMed ID: 25813704
[TBL] [Abstract][Full Text] [Related]
5. α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.
Quik M; Campos C; Bordia T; Strachan JP; Zhang J; McIntosh JM; Letchworth S; Jordan K
Neuropharmacology; 2013 Aug; 71():191-203. PubMed ID: 23583932
[TBL] [Abstract][Full Text] [Related]
6. Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease.
Quik M; Zhang D; McGregor M; Bordia T
Biochem Pharmacol; 2015 Oct; 97(4):399-407. PubMed ID: 26093062
[TBL] [Abstract][Full Text] [Related]
7. Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.
Quik M; Zhang D; Perez XA; Bordia T
Pharmacol Ther; 2014 Oct; 144(1):50-9. PubMed ID: 24836728
[TBL] [Abstract][Full Text] [Related]
8. The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.
Bordia T; McIntosh JM; Quik M
J Neurochem; 2013 Apr; 125(2):291-302. PubMed ID: 23373725
[TBL] [Abstract][Full Text] [Related]
9. Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization.
Bordia T; Campos C; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2010 Jun; 333(3):929-38. PubMed ID: 20200117
[TBL] [Abstract][Full Text] [Related]
10. Cotinine selectively activates a subpopulation of alpha3/alpha6beta2 nicotinic receptors in monkey striatum.
O'Leary K; Parameswaran N; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2008 May; 325(2):646-54. PubMed ID: 18305015
[TBL] [Abstract][Full Text] [Related]
11. Genetic deletion of the adenosine A(2A) receptor prevents nicotine-induced upregulation of α7, but not α4β2* nicotinic acetylcholine receptor binding in the brain.
Metaxas A; Al-Hasani R; Farshim P; Tubby K; Berwick A; Ledent C; Hourani S; Kitchen I; Bailey A
Neuropharmacology; 2013 Aug; 71():228-36. PubMed ID: 23583933
[TBL] [Abstract][Full Text] [Related]
12. Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.
Huang LZ; Campos C; Ly J; Ivy Carroll F; Quik M
Neuropharmacology; 2011 May; 60(6):861-8. PubMed ID: 21232546
[TBL] [Abstract][Full Text] [Related]
13. Focus on α4β2* and α6β2* nAChRs for Parkinson's Disease Therapeutics.
Pérez XA; Quik M
Mol Cell Pharmacol; 2011; 3(1):1-6. PubMed ID: 21499569
[TBL] [Abstract][Full Text] [Related]
14. Characterization of AN6001, a positive allosteric modulator of α6β2-containing nicotinic acetylcholine receptors.
van Hout M; Klein J; Ahring PK; Brown DT; Thaneshwaran S; Dos Santos AB; Jensen AA; Kohlmeier KA; Christophersen P; Dyhring T
Biochem Pharmacol; 2020 Apr; 174():113788. PubMed ID: 31887290
[TBL] [Abstract][Full Text] [Related]
15. A role for α4(non-α6)* nicotinic acetylcholine receptors in motor behavior.
Soll LG; Grady SR; Salminen O; Marks MJ; Tapper AR
Neuropharmacology; 2013 Oct; 73():19-30. PubMed ID: 23688922
[TBL] [Abstract][Full Text] [Related]
16. Multiple roles for nicotine in Parkinson's disease.
Quik M; Huang LZ; Parameswaran N; Bordia T; Campos C; Perez XA
Biochem Pharmacol; 2009 Oct; 78(7):677-85. PubMed ID: 19433069
[TBL] [Abstract][Full Text] [Related]
17. Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and function.
Perez XA; Bordia T; McIntosh JM; Grady SR; Quik M
Mol Pharmacol; 2008 Sep; 74(3):844-53. PubMed ID: 18583454
[TBL] [Abstract][Full Text] [Related]
18. The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions.
Bordia T; McGregor M; Papke RL; Decker MW; McIntosh JM; Quik M
Exp Neurol; 2015 Jan; 263():277-84. PubMed ID: 25261754
[TBL] [Abstract][Full Text] [Related]
19. The novel α7β2-nicotinic acetylcholine receptor subtype is expressed in mouse and human basal forebrain: biochemical and pharmacological characterization.
Moretti M; Zoli M; George AA; Lukas RJ; Pistillo F; Maskos U; Whiteaker P; Gotti C
Mol Pharmacol; 2014 Sep; 86(3):306-17. PubMed ID: 25002271
[TBL] [Abstract][Full Text] [Related]
20. Diverse strategies targeting α7 homomeric and α6β2* heteromeric nicotinic acetylcholine receptors for smoking cessation.
Brunzell DH; McIntosh JM; Papke RL
Ann N Y Acad Sci; 2014 Oct; 1327(1):27-45. PubMed ID: 24730978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
